Verrica Pharmaceuticals Inc. (VRCA) Dividend History

Verrica Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing dermatology solutions. The company's lead products target FDA-approved indications for the treatment of skin conditions caused by viruses, such as molluscum contagiosum and common warts. Verrica aims to address unmet medical needs with innovative and well-tolerated therapies for dermatological issues.

10 North High Street, West Chester, PA, 19380
Phone: 484-453-3300
Website: https://www.verrica.com

Dividend History

Verrica Pharmaceuticals Inc. currently does not pay dividends

Company News

  • Verrica Posts Profit in Fiscal Q2

    Verrica Pharmaceuticals reported strong Q2 2025 financial results, with non-GAAP EPS of $0.25 and GAAP revenue of $12.7 million, significantly exceeding analyst expectations. The company saw improved performance driven by YCANTH product sales and a major milestone payment from Torii Pharmaceutical.

    The Motley Fool
  • Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

    Verrica Pharmaceuticals announced the acceptance of two abstracts featuring positive preliminary results from a Phase 2 study of its investigational therapy VP-315 for the treatment of basal cell carcinoma. The data showed promising safety, tolerability, and antitumor efficacy.

    GlobeNewswire Inc.
  • Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Roth MKM cut the price target for Roblox Corporation (NYSE:RBLX) from $55 to $35. Roth MKM analyst Eric Handler downgraded the stock from Buy to Neutral. Roblox shares fell 1.6% to close at $30.96 on Monday. See how other analysts view this stock. Needham boosted the price target for Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) from $8 to $16. Needham analyst Serge Belanger maintained a Buy rating. Verrica Pharmaceuticals shares jumped 19.5% to close at $9.56 on Monday. See how other analysts view this stock. Baird cut Fortrea Holdings Inc. (NASDAQ:FTRE) price target from $45 to $36. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. Fortrea ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: AGYS AIR FTRE NTRA PLNT RBLX SAM
  • Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

    Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 29.63% and 41.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: COSM
  • Hot Penny Stocks to Buy Now? 3 to Watch in Early July 

    Check these penny stocks out for your watchlist The post Hot Penny Stocks to Buy Now? 3 to Watch in Early July  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: AKBA
Page data last updated 09/07/2025 04:16:55 UTC